Interrupting ErbB receptor transactivation by a combined inhibitor of ADAM10 and ADAM17 reduced non-small-lung-cancer-cell formation, subcutaneous tumor growth, and breast cancer and fibroplasia [259, 260]. The gene discussed is ADAM17; the disease is breast cancer.